Implantica Expands RefluxStop® Reach with New Center in Spain

Implantica Expands RefluxStop® Center of Excellence in Spain

Implantica AG, a prominent player in the medtech landscape, has recently announced the opening of its 20th RefluxStop® Center of Excellence. This center is housed within the MD Anderson Cancer Center Madrid-Hospiten, which is part of the globally recognized MD Anderson Cancer Group based in the U.S. This significant milestone symbolizes not only the growth of Implantica in the Spanish market but also its dedication to providing advanced treatment options for patients suffering from gastroesophageal reflux disease (GERD).

The groundbreaking RefluxStop® procedure was successfully performed by Dr. Oscar Alonso, a leading GI Surgical Oncologist and Head of Robotic Gastrointestinal Surgery at the MD Anderson Cancer Center Madrid-Hospiten. Dr. Daniel Sanchez from H. Univ. Infanta Sofía acted as a proctor for this notable event. With over 1 billion individuals worldwide affected by acid reflux, the establishment of this fiftieth centre signifies a vital step towards improving patient outcomes in this area of healthcare.

Since its inception in 2000, the Madrid branch of the MD Anderson Cancer Center has offered comprehensive care to over 65,000 patients, including those requiring interventions unrelated to cancer. The introduction of the RefluxStop® procedure adds another dimension to its portfolio by addressing one of the most common ailments among adults today.

Dr. Alonso noted a pivotal shift in the approach to anti-reflux surgery, stating, "We are witnessing a growing paradigm shift in anti-reflux surgery that emphasizes restoring the body's natural anatomy rather than restricting the esophagus." He expressed excitement for the introduction of RefluxStop, especially given its promising clinical results. The recently published five-year clinical data from an extensive multicenter prospective trial demonstrated an impressive average improvement of 90% or greater in patients' quality-of-life scores related to GERD, marking a significant breakthrough for surgical interventions in this field.

Dr. Peter Forsell, the CEO and founder of Implantica and inventor of the RefluxStop device, expressed his enthusiasm for the rapid expansion of the procedure's availability throughout Spain. He stated, "Having twenty hospitals in Spain performing the RefluxStop® procedure is a significant achievement… This milestone underscores the market potential for RefluxStop, fueled by strong surgical demand and surgeon interest."

The pressing statistical reality that around 15% of the population in Spain suffers from GERD establishes an urgent need for effective surgical solutions. According to Forsell, the unique design of the RefluxStop device reconstructs the body's natural anti-reflux barrier without compressing the esophagus, thus aiming to minimize side effects commonly associated with traditional surgical techniques.

Apart from its revolutionary approach towards treating GERD, Implantica also possesses a wide range of patent-protected products in a pipeline that integrates eHealth technologies, facilitating remote patient monitoring and management.

Implantica is listed on the Nasdaq First North Premier Growth Market in Stockholm, reflecting its growing influence and recognition within the medical technology sector. As it aims to expand the RefluxStop procedure to more countries, the company seeks to improve care for millions of patients suffering from GERD worldwide.

In conjunction with these advancements, the commitment displayed by MD Anderson Cancer Center Madrid-Hospiten towards enhancing patient quality of life continues to align with Implantica's vision. With increasing collaboration between institutions dedicated to innovative medical solutions, the future looks promising for GERD management and treatment.

For more information about Implantica and its innovative solutions, visitors can go to Implantica's official website.